AlphAIAlphAI — Financial news for AI agents
rttnews.comNOV 41 min read$PRGO

Perrigo Company Slips To Loss In Q3

Perrigo Company reported Q3 net sales of $989M, down from $1.04B last year. It posted a loss of $14.3M, or $0.10 per share, compared to a profit of $12.7M, or $0.09 per share, in the prior year. Adjusted earnings fell to $0.60 per share from $0.80. The company expects fiscal 2026 adjusted earnings of $2.25 to $2.45 per share. Pre-market, PRGO shares were up 1.02% at $15.84.

Original reporting
rttnews.com
Published Nov 4, 2026, 12:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Perrigo Company Slips To Loss In Q3 — source image
Source · rttnews.com
Decision brief

The 30-second read

$PRGOBearishHigh
01

Why it matters

The earnings miss and guidance cut could trigger sell‑offs, but the pre‑market uptick hints at short‑term buying interest.

02

Market read

First‑report earnings loss with guidance downgrade for a mid‑cap health‑care stock.

03

What to watch

Inventory positioning ahead of the cough‑and‑cold season may improve margins later in the year.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Perrigo is a global consumer‑health company listed on the NYSE (PRGO).

Company-level read

Ticker impact

$PRGOBearishHigh confidence
Context

Perrigo reported a Q3 loss and lowered FY2026 earnings guidance, prompting a 1% pre‑market rise.

Expected impact

downward pressure as investors price in the loss and lower guidance

Evidence & confidence

The company posted a loss of $14.3 M versus prior‑year profit and cut FY2026 adjusted EPS to $2.25‑$2.45, a material downgrade.

Market effects

Sector

Consumer health segment may see broader scrutiny as earnings miss signals demand softness.

Regional

U.S. listed consumer‑health stocks could face short‑term pressure.

Global

Limited to investors tracking mid‑cap health‑care names.

Counterpoint

What could challenge this read

The modest pre‑market rise suggests some investors view the loss as a buying opportunity given the stock's valuation.

Key entities

  • Company
    Perrigo Company plc

    Issuer of the earnings release.

Read at source← All news

StoryPerrigo reports Q3 loss, updates outlook and announces Infant Formula divestiture

Also covered by

5 outlets

Related articles

NOV 4
$PRGOMed

Perrigo 2026: Revenue $988.6M, EPS ($0.2) — 10-Q Summary

Perrigo reported 2026 nine-month net sales of $988.6M, down 5.2% YoY, and a net loss of $27.5M, compared to a net income of $7.5M in the prior year. Diluted loss per share was $0.2, versus earnings of $0.05. The decline was attributed to soft consumer demand, lower retailer inventories, and the sale of the Dermacosmetics business. Perrigo plans to sell its Infant Formula business for up to $175M and expects $80M-$100M in annual savings from a two-year efficiency program.

tradingview.com1 min
NOV 4
$PRGOHighAI 8/10

Perrigo Q3 2026 slides show sequential gains amid portfolio shift

Perrigo (NYSE:PRGO) reported Q3 2026 earnings with adjusted EPS of $0.60, beating estimates, while revenue of $989M missed expectations. The stock rose 4.62% to $16.43. Despite year-over-year declines, sequential improvements were noted in sales and margins. The company announced a divestiture of its Infant Formula business for $40M upfront and up to $135M in milestones, part of its strategic transformation.

investing.com2 min
NOV 4
$PRGOMedAI 8/10

Perrigo beats earnings but misses on revenue

Perrigo (PRGO) reported Q3 earnings of $0.60 per share, beating estimates by $0.05, but revenue of $989M missed expectations and fell 5.2% YoY. Full-year 2026 EPS guidance was raised to $2.15-$2.35, above consensus. The company plans to sell its Infant Formula business for up to $175M, expecting an impairment loss of $275M-$375M in Q4. Shares rose 0.89% in pre-market trading.

investing.com1 min
NOV 4
$PRGOMed

Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations

PERRIGO Co plc (PRGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations • Execution of Three-S plan driving sequential improvement in operating results and market share gains across U.S. Store Brand OTC and key European brands • Infant Formula divestiture exp

SEC EDGAR 8-K3 min
NOV 4
$PRGOMedAI 8/10

Perrigo: Q3 Earnings Snapshot

Perrigo (PRGO) reported a Q3 loss of $27.5M, or 20 cents per share, but adjusted earnings of 60 cents beat estimates. Revenue of $988.6M missed expectations. The company forecasts full-year earnings of $2.25-$2.45 per share.

finance.yahoo.com1 min